Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Epoxomicin: Selective 20S Proteasome Inhibitor for Protei...

    2025-11-06

    Epoxomicin: Selective 20S Proteasome Inhibitor for Protein Degradation Assays

    Executive Summary: Epoxomicin is a naturally occurring, irreversible 20S proteasome inhibitor with exceptional selectivity for chymotrypsin-like activity (IC50=4 nM) demonstrated in cell-based and animal models (Liu et al., 2021). It covalently modifies active site residues via its α',β'-epoxyketone moiety, underpinning its potency and irreversibility. Epoxomicin has been validated for dissecting the ubiquitin-proteasome pathway in inflammation, protein degradation, and neurodegenerative disease studies (Oprozomib.org). The compound is insoluble in water but highly soluble in DMSO (≥27.73 mg/mL), with recommended storage at -20°C to preserve stability. Experimental reproducibility is enhanced by its robust performance in HEK293T and related cell assays, making it a gold-standard reagent for mechanistic and translational research (ApexBio A2606).

    Biological Rationale

    The ubiquitin-proteasome pathway is central to regulated protein degradation in eukaryotic cells. Disruption of this pathway affects cell signaling, inflammation, and cell death. Proteasome inhibitors are critical for elucidating these processes and for modeling diseases such as cancer and neurodegeneration. Epoxomicin provides an atomic-level tool for selective inhibition of the 20S proteasome’s chymotrypsin-like activity, enabling precise interrogation of proteasomal function (ps-341.com). Compared to broad-spectrum inhibitors, Epoxomicin’s selectivity minimizes off-target effects, supporting its use in delineating ubiquitin-dependent proteostasis. The biological need for selective, irreversible proteasome inhibition has been underscored by research into viral immune evasion mechanisms, where proteasome-mediated degradation of immune adaptors such as RIPK3 is functionally significant (Liu et al., 2021).

    Mechanism of Action of Epoxomicin

    Epoxomicin exerts its effect by forming a covalent bond with the N-terminal threonine of the 20S proteasome’s catalytic subunits via its α',β'-epoxyketone pharmacophore. This reaction irreversibly inhibits the chymotrypsin-like (β5), trypsin-like (β2), and, to a lesser extent, peptidyl-glutamyl peptide hydrolysis (β1) activities. The IC50 for chymotrypsin-like inhibition in cell lysates is 4 nM at 37°C, pH 7.4, in DMSO buffer (ApexBio). Covalent modification ensures sustained inhibition, even after compound washout, distinguishing Epoxomicin from reversible inhibitors. This mechanism enables researchers to dissect the temporal dynamics of proteasome-dependent protein turnover in living cells and tissues (epoxomicin.com). Importantly, this specificity is retained in various model systems, including HEK293T cells and animal models of inflammation and neurodegeneration.

    Evidence & Benchmarks

    • Epoxomicin irreversibly inhibits 20S proteasome chymotrypsin-like activity with an IC50 of 4 nM in cell lysates (ApexBio product data: product page).
    • It effectively blocks proteasome-mediated degradation of RIPK3, a key necroptosis adaptor, in virus-infected models, supporting studies of inflammation and cell death (Liu et al., 2021).
    • Reduces inflammation and viral replication in animal models by interfering with the ubiquitin-proteasome pathway (Liu et al., 2021).
    • Provides robust results in protein degradation assays and cellular models of Parkinson’s disease (Oprozomib.org).
    • Maintains stability and potency when stored at -20°C in DMSO for at least 6 months (ApexBio technical documentation: ApexBio).
    • Epoxomicin’s selectivity and irreversibility outperform other peptide aldehyde proteasome inhibitors in maintaining assay reproducibility (ps-341.com).

    This article clarifies the mechanistic benchmarks reported in previous summaries by adding recent peer-reviewed evidence and detailed application parameters.

    Applications, Limits & Misconceptions

    Epoxomicin is widely used in:

    • Dissecting the ubiquitin-proteasome pathway in cell-based and animal models (epoxomicin.com).
    • Protein degradation assays in HEK293T and other mammalian cells.
    • Modeling Parkinson’s disease and other neurodegenerative conditions where proteostasis is impaired.
    • Studying anti-inflammatory pathways and viral immune evasion by blocking degradation of signaling adaptors (Liu et al., 2021).
    • Screening for proteasome inhibitor resistance in cancer cell lines.

    For broader context, prior reviews summarized general workflows; this article provides updated mechanistic details and limitations.

    Common Pitfalls or Misconceptions

    • Epoxomicin is ineffective in aqueous buffers due to insolubility; always prepare in DMSO or ethanol at ≥27.73 mg/mL and ≥77.4 mg/mL, respectively.
    • Not all proteasomal activities are equally inhibited: chymotrypsin-like activity is potently blocked, while trypsin- and caspase-like activities are less sensitive (ApexBio).
    • Irreversible inhibition means effects persist after compound removal; time-course experiments must account for lack of recovery.
    • Not suitable for in vivo use in humans as a therapeutic due to pharmacokinetics and safety profiles; its use is restricted to research settings.
    • Proteasome-independent degradation pathways (e.g., lysosomal, autophagic) are not affected by Epoxomicin.

    Workflow Integration & Parameters

    For optimal use, dissolve Epoxomicin in DMSO at stock concentrations ≥10 mM. Working solutions are typically 10–1000 nM in cell culture, depending on cell type and assay design. Avoid repeated freeze-thaw cycles; store stocks at -20°C. Use within 6 months for maximal potency. In protein degradation assays, incubate with cells for 30–120 minutes at 37°C. Monitor for off-target cytotoxicity in cell lines with low proteasome activity. The A2606 Epoxomicin kit provides ready-to-use solid reagent for rapid workflow integration. Refer to advanced workflow guides for ER-stress and proteostasis protocols not covered in basic product sheets.

    Conclusion & Outlook

    Epoxomicin remains the gold standard for experimental proteasome inhibition due to its selectivity, irreversible mechanism, and robust performance in key cellular models. Ongoing research continues to reveal new roles for 20S proteasome inhibitors in immunology, neurodegeneration, and systems biology. Future developments may include engineered derivatives with improved pharmacokinetics or targeted delivery. For high-fidelity dissection of the ubiquitin-proteasome pathway, Epoxomicin offers unmatched reproducibility and mechanistic clarity, as detailed in the sources above.